AR079369A1 - Uso terapeutico de conjugados proteina-polimero - Google Patents
Uso terapeutico de conjugados proteina-polimeroInfo
- Publication number
- AR079369A1 AR079369A1 ARP100104587A ARP100104587A AR079369A1 AR 079369 A1 AR079369 A1 AR 079369A1 AR P100104587 A ARP100104587 A AR P100104587A AR P100104587 A ARP100104587 A AR P100104587A AR 079369 A1 AR079369 A1 AR 079369A1
- Authority
- AR
- Argentina
- Prior art keywords
- moiety
- protein
- binder
- disease
- therapeutic use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Abstract
Reivindicacion 1: Un método para tratar una enfermedad, que comprende administrar a un sujeto que lo necesita una cantidad efectiva de un conjugado sustancialmente puro que consta de por lo menos un resto polimérico, un resto de proteína y un ligando, donde dicho por lo menos un resto polimérico está acoplado al ligante, el átomo de nitrogeno del término N del resto proteico está unido al ligante y el ligante es un enlace covalente, alquileno C1-10, alquenileno C2-10 o alquinileno C2-10, donde la enfermedad es mielofibrosis idiopática, policitemia vera o trombocitemia esencial. Reivindicacion 2: El método de acuerdo con la reivindicacion 1, en el cual el resto de proteína es un resto iriterferon alfa2b modificado que contiene 1-4 residuos aminoácidos adicionales en el término N.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28541109P | 2009-12-10 | 2009-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079369A1 true AR079369A1 (es) | 2012-01-18 |
Family
ID=44146181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104587A AR079369A1 (es) | 2009-12-10 | 2010-12-10 | Uso terapeutico de conjugados proteina-polimero |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8617532B2 (es) |
| EP (1) | EP2509593B1 (es) |
| JP (1) | JP5547816B2 (es) |
| KR (1) | KR101782084B1 (es) |
| CN (1) | CN102724980B (es) |
| AR (1) | AR079369A1 (es) |
| AU (1) | AU2010328067B2 (es) |
| BR (1) | BR112012014017B1 (es) |
| CA (1) | CA2782624C (es) |
| CL (1) | CL2012001503A1 (es) |
| CY (1) | CY1122901T1 (es) |
| DK (1) | DK2509593T3 (es) |
| EA (1) | EA022354B9 (es) |
| ES (1) | ES2786025T3 (es) |
| HK (1) | HK1176015A1 (es) |
| HR (1) | HRP20200678T1 (es) |
| HU (1) | HUE049051T2 (es) |
| IL (1) | IL220249A0 (es) |
| LT (1) | LT2509593T (es) |
| MA (1) | MA33913B1 (es) |
| MX (1) | MX337705B (es) |
| MY (1) | MY169961A (es) |
| NZ (1) | NZ600528A (es) |
| PL (1) | PL2509593T3 (es) |
| PT (1) | PT2509593T (es) |
| RS (1) | RS60336B1 (es) |
| SG (1) | SG181084A1 (es) |
| SI (1) | SI2509593T1 (es) |
| TN (1) | TN2012000256A1 (es) |
| UA (1) | UA109646C2 (es) |
| WO (1) | WO2011072138A2 (es) |
| ZA (1) | ZA201205056B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3215193T3 (pl) * | 2014-11-06 | 2024-03-18 | Pharmaessentia Corporation | Reżim podawania pegylowanego interferonu |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20074024B (en) * | 2002-01-18 | 2007-01-10 | Biogen Idec Inc | Polyalkylene glycol comprising a radical for conjugation of biologically active compound |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| CL2008002399A1 (es) * | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| ES2382124T3 (es) * | 2007-09-04 | 2012-06-05 | Biosteed Gene Expression Tech. Co., Ltd. | Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este |
| GB0908393D0 (en) * | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
-
2010
- 2010-09-12 UA UAA201208492A patent/UA109646C2/ru unknown
- 2010-12-09 PT PT108366931T patent/PT2509593T/pt unknown
- 2010-12-09 RS RS20200469A patent/RS60336B1/sr unknown
- 2010-12-09 MA MA35051A patent/MA33913B1/fr unknown
- 2010-12-09 CN CN201080056068.1A patent/CN102724980B/zh active Active
- 2010-12-09 EP EP10836693.1A patent/EP2509593B1/en active Active
- 2010-12-09 DK DK10836693.1T patent/DK2509593T3/da active
- 2010-12-09 MX MX2012006132A patent/MX337705B/es active IP Right Grant
- 2010-12-09 AU AU2010328067A patent/AU2010328067B2/en active Active
- 2010-12-09 MY MYPI2012002421A patent/MY169961A/en unknown
- 2010-12-09 HU HUE10836693A patent/HUE049051T2/hu unknown
- 2010-12-09 CA CA2782624A patent/CA2782624C/en active Active
- 2010-12-09 PL PL10836693T patent/PL2509593T3/pl unknown
- 2010-12-09 NZ NZ600528A patent/NZ600528A/en unknown
- 2010-12-09 US US12/964,408 patent/US8617532B2/en active Active
- 2010-12-09 SI SI201032008T patent/SI2509593T1/sl unknown
- 2010-12-09 BR BR112012014017-5A patent/BR112012014017B1/pt active IP Right Grant
- 2010-12-09 LT LTEP10836693.1T patent/LT2509593T/lt unknown
- 2010-12-09 SG SG2012038964A patent/SG181084A1/en unknown
- 2010-12-09 EA EA201200865A patent/EA022354B9/ru unknown
- 2010-12-09 KR KR1020127015843A patent/KR101782084B1/ko active IP Right Grant
- 2010-12-09 JP JP2012543282A patent/JP5547816B2/ja active Active
- 2010-12-09 ES ES10836693T patent/ES2786025T3/es active Active
- 2010-12-09 WO PCT/US2010/059714 patent/WO2011072138A2/en active Application Filing
- 2010-12-10 AR ARP100104587A patent/AR079369A1/es unknown
-
2012
- 2012-05-24 TN TNP2012000256A patent/TN2012000256A1/en unknown
- 2012-06-07 IL IL220249A patent/IL220249A0/en active IP Right Grant
- 2012-06-07 CL CL2012001503A patent/CL2012001503A1/es unknown
- 2012-07-06 ZA ZA2012/05056A patent/ZA201205056B/en unknown
-
2013
- 2013-03-20 HK HK13103501.1A patent/HK1176015A1/xx unknown
-
2020
- 2020-04-28 HR HRP20200678TT patent/HRP20200678T1/hr unknown
- 2020-05-07 CY CY20201100422T patent/CY1122901T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200870352A1 (ru) | Жидкие композиции и способы для увеличения ткани | |
| PE20171512A1 (es) | Anticuerpos anti-fap | |
| NZ592509A (en) | HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same | |
| CL2012001178A1 (es) | 2-[(4s)-6-(4-cloro-fenil)-1-metil-8-(metiloxi)-4h-[1,2,4]-triazolo-[4,3-a][1,4]-benzo-diazepin-4-il]-n-etil-acetamida o una sal; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas y cancer. | |
| EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| BRPI0912411A8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro. | |
| MX2012008603A (es) | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. | |
| NI201100150A (es) | Sistemas basados en conjugados para entrega farmacológica controlada. | |
| AR074777A1 (es) | Proteinas de union a antigeno | |
| EA201070657A1 (ru) | Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина | |
| ES2616789T8 (es) | Inhibidores de tirosina cinasa de Bruton | |
| EP2896632A3 (en) | Material and methods for treating or preventing HER-3 associated diseases | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| GT200900188A (es) | Anticuerpos neutralizantes del citomegalovirus humano y su uso. | |
| CL2009000697A1 (es) | Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras. | |
| BRPI0905369B8 (pt) | composição farmacêutica, uso da composição farmacêutica e kit compartimentado | |
| BR112015009280A2 (pt) | preparações liofilizadas de melfalana flufenamida | |
| BR112013010829A2 (pt) | composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma | |
| WO2013096829A3 (en) | Activation of cellular assault processes in the treatment of glioblastoma multiforme | |
| PH12020500417A1 (en) | Anti-efgr antibody drug conjugates (adc) and uses thereof | |
| AR079369A1 (es) | Uso terapeutico de conjugados proteina-polimero | |
| TR200806300A2 (tr) | Çözünürlük artırıcı farmasötlk formulasyon | |
| EA200970022A1 (ru) | Комбинированные препараты, содержащие бифепрунокс и l-допу | |
| PE20141189A1 (es) | Preparacion de liberacion sostenida | |
| WO2009137436A3 (en) | Peptide conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |